Introduction - Advances in our understanding of insomnia and its management

Sleep Medicine

Volumn 8, Issue SUPPL. 3, 2007, Pages 25-26

  Roth, Thomas ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE;

COGNITIVE THERAPY; COMORBIDITY; EDITORIAL; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SLEEP AROUSAL DISORDER; SLEEP WAKING CYCLE; SUPRACHIASMATIC NUCLEUS;

COGNITIVE THERAPY; CORTICOTROPIN-RELEASING HORMONE; HUMANS; HYPNOTICS AND SEDATIVES; MELATONIN; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 36248980926     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2007.10.001     Document Type: Editorial

References (15)

1. National Institutes of Health, State of the science conference statement on manifestations and management of chronic insomnia in adults June 13-15, 2005. Sleep 2005;28:1049-1057.
2. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. fourth ed. text revised. Washington DC: American Psychiatric Association; 2000.
3. Edinger J.D., Bonnett M.H., Bootzin R.R., et al. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine work group. Sleep 27 (2004) 1567-1596
4. Fava M., McCall W.V., Krystal A., Wessel T., Rubens R., Caron J., et al. Eszopiclone co-administered coexisting with major depressive disorder. Biol Psychiatry 59 (2006) 1052-1060
5. Roehrs T., Hyde M., Blaisdell B., Greenwalk M., and Roth T. Sleep loss and REM sleep loss are hyperalgesic. Sleep 29 (2006) 145-151
6. Vgontzas A.N., Tsigos C., Bixler E.O., et al. Chronic insomnia and activity of the stress system: a preliminary study. J Psychosom Res 45 (1998) 21-31
7. Bonnet M.H., and Arand D.L. 24-Hour metabolic rate in insomniacs and matched normal sleepers. Sleep 18 (1995) 581-588
8. Lushington K., Dawson D., and Lack L. Core body temperature is elevated during constant wakefulness in elderly poor sleepers. Sleep 23 (2000) 504-510
9. Nofzinger E.A., Buysse D., Germain A., et al. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 161 (2004) 2126-2128
10. Perlis M.L., Smith M.T., Andrews P.J., Orff H., and Giles D.E. Beta/gamma EEG activity in patients with primary and secondary insomnia and good sleeper controls. Sleep 24 (2001) 110-117
11. Cortoos A., Verstraeten E., and Cluydts R. Neurophysiological aspects of primary insomnia: implications for its treatment. Sleep Med Rev 10 (2006) 255-266
12. Roth T., Roehrs T., and Pies R. Insomnia: pathophysiology and implications for treatment. Sleep Med Rev 11 (2007) 71-79
13. Buckley T., and Schatzberg A. Review: on the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab 90 (2005) 3106-3114
14. Vgontzas A.N., Bixler E.O., Lin H., et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 86 (2001) 3787-3794
15. Krystal A.D., Walsh J.K., Laska E., et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26 (2003) 793-799